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Human metapneumovirus (hMPV) is a recently discovered paramyxovirus that causes upper and lower
respiratory tract infections in infants, the elderly, and immunocompromised individuals worldwide. Here, we
developed Venezuelan equine encephalitis virus replicon particles (VRPs) encoding hMPV fusion (F) or
attachment (G) glycoproteins and evaluated the immunogenicity and protective efficacy of these vaccine
candidates in mice and cotton rats. VRPs encoding hMPV F protein, when administered intranasally, induced
F-specific virus-neutralizing antibodies in serum and immunoglobulin A (IgA) antibodies in secretions at the
respiratory mucosa. Challenge virus replication was reduced significantly in both the upper and lower respi-
ratory tracts following intranasal hMPV challenge in these animals. However, vaccination with hMPV G
protein VRPs did not induce neutralizing antibodies or protect animals from hMPV challenge. Close exami-
nation of the histopathology of the lungs of VRP-MPV F-vaccinated animals following hMPV challenge
revealed no enhancement of inflammation or mucus production. Aberrant cytokine gene expression was not
detected in these animals. Together, these results represent an important first step toward the use of VRPs
encoding hMPV F proteins as a prophylactic vaccine for hMPV.
Human metapneumovirus (hMPV) is a paramyxovirus re-
cently discovered in young children with respiratory tract dis-
ease (40). Subsequent studies showed that hMPV is a causative
agent for both upper and lower respiratory tract infections in
infants and young children (6, 15, 16, 46, 47). The spectrum of
clinical illness ranges from mild upper respiratory tract disease
to severe bronchiolitis and pneumonia, similar to that seen in
respiratory syncytial virus (RSV) infection. Children and adults
with comorbid conditions, such as those with congenital heart
or lung diseases, cancer, or immunodeficiency, are at particular
risk for severe respiratory disease from hMPV infection (28,
48). Epidemiology studies have suggested that hMPV infection
causes lower respiratory tract disease in 5 to 15% of otherwise-
healthy infants and young children (6, 16, 22, 27, 28, 47).
Recurrent infection with hMPV also has been documented
(14, 50). This newly identified virus represents one of the
leading causes of acute viral respiratory tract infections in this
population and thus represents a valid target for the develop-
ment of candidate vaccines.
The fusion (F) and attachment (G) proteins are the major
surface glycoproteins on hMPV, and they exhibit significant
homology with the F and G proteins of RSV. Genetic analysis
divides hMPV into two major subgroups (A and B) based on
sequence comparison of the F and G genes in various clinical
isolates (2, 4). The subgroups can be further divided into sub-
lineages designated A1, A2, B1, and B2. The percent amino
acid homology in the F protein among isolates reaches 95%
and is highly conserved between the subgroups (7, 34). The G
protein, however, shows significant amino acid diversification,
with nucleotide sequence homology among field isolates rang-
ing from 34 to 100%, depending on inter- and intrasubgroup
comparisons (1, 4). For RSV, F and G proteins are the major
antigenic targets for neutralizing antibodies. High titers of
serum neutralizing antibodies are sufficient to protect the
lower respiratory tract against RSV infection (11). Therefore,
F and G proteins have been used singly or in combinations in
various experimental RSV vaccines.
A number of experimental vaccines have been described for
hMPV. These include subunit F protein vaccine (13), live-
attenuated hMPV with gene deletions (5), and a chimeric,
live-attenuated parainfluenza virus vaccine that incorporates
the hMPV F, G, or SH gene (33, 35, 36). Although proven to
be immunogenic in animal models, there are significant hur-
dles for some of these vaccines to be used in very young infants,
the principal target population for hMPV vaccines. The pres-
ence of circulating maternal antibodies against hMPV glyco-
proteins and most of the candidate viral vectors, such as para-
influenza virus, is of concern and could blunt the efficacy of
these vaccines in vivo. Furthermore, the ability to induce a
mucosal response is desirable for successful immunization
against respiratory viruses.
In this study, we developed alphavirus replicon particles
(VRPs) based on Venezuelan equine encephalitis virus (VEE)
that encode hMPV F or G proteins and tested their immuno-
genicity in mice and cotton rats. There is no data to date on
immunization for hMPV with VRPs, virus-like particles, or
related nonreplicating particle vaccine candidates. VEE repli-
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con particles have several significant advantages over other
viral vaccine candidates. First, there is limited preexisting im-
munity to VEE in the target population, making them less
likely to be neutralized in vaccine recipients. Second, these
replicons are potential vaccine vectors for use in very young
infants, since they are encapsidated in a heterologous VEE
coat that shields them from maternal hMPV-specific antibod-
ies. Recently, these replicons were found to induce neutraliz-
ing antibody responses in young mice, regardless of the mater-
nal immune status (45). In addition, these VEE replicon
particles appear to induce novel aspects of mucosal immunity
that other approaches do not. In particular, VRPs target lymph
nodes, and they have systemic and mucosal adjuvant properties
(38). Prior experience with VRPs has proven them to be safe
for use in a variety of animals and healthy young adult human
subjects (10). Human clinical trials to evaluate safety and im-
munogenicity have been conducted or are in the process of
testing for at least four antigenic targets, including human
immunodeficiency virus, cytomegalovirus, influenza virus, and
carcinoembryonic antigen. In animals, these particles induce
mucosal immune responses after parenteral inoculation and
confer protection to the primary mucosal target tissue (38).
Here, we demonstrate that VRPs encoding subgroup A
MPV F protein induce both systemic and mucosal humoral
responses. High-titer neutralizing antibodies against subgroup
A1 and A2 viruses were induced in vaccinated animals; how-
ever, these antibodies were not effective in neutralizing sub-
group B viruses in vitro. When vaccinated animals were chal-
lenged with an hMPV subgroup A2 strain intranasally, virus
replication was reduced significantly in both the lungs and
nasal turbinates. Histopathology showed no enhanced inflam-
mation or mucus production in vaccinated mice compared to
animals that received live hMPV vaccine. In contrast, animals
vaccinated with VRPs encoding MPV G did not generate neu-
tralizing antibodies and were not protected against hMPV live
virus challenge. These findings provide proof-of-principle that
VEE VRPs expressing the MPV F protein can be used in
hMPV prophylaxis.
MATERIALS AND METHODS
Animals and cell lines. Five- to 6-week-old DBA/2 mice and cotton rats were
purchased from Harlan (Indianapolis, IN) and Virion Systems (Rockville, MD),
respectively. Animals were housed in microisolator cages throughout the study.
All experimental procedures performed were approved by the Institutional An-
imal Care and Use Committee at Vanderbilt University Medical Center.
LLC-MK2 cells were obtained from ATCC (CCL-7) and maintained in
OptiMEM I medium (Invitrogen) supplemented with 2% fetal bovine serum, 4 mM
L-glutamine, 5 g/ml amphotericin B, and 50 g/ml gentamicin sulfate at 37°C
with 5% CO2. BHK-21 cells were obtained from ATCC (CCL-10) and main-
tained in Eagle’s minimum essential medium supplemented with 10% fetal
bovine serum, 4 mM L-glutamine, 5 g/ml amphotericin B, and 50 g/ml gen-
tamicin sulfate at 37°C with 5% CO2.
VEE constructs and generation of VRPs encoding hMPV F or G genes. The
method of construction and packaging of VRPs was described previously (32).
Briefly, the hMPV F or G protein-encoding DNA sequences from the subgroup
A2 hMPV wild-type strain TN/94-49 were inserted behind the 26S subgenomic
promoter in a VEE replicon plasmid, pVR21. pVR21 was derived from mu-
tagenesis of a cDNA clone of the Trinidad donkey strain of VEE.
For generation of VRPs, capped RNA transcripts of the pVR21 plasmid
containing hMPV F or G genes were generated in vitro with the mMESSAGE
mMACHINE T7 kit (Ambion, Austin, TX). Similarly, helper transcripts that
encoded the VEE virus capsid and glycoprotein genes derived from the attenu-
ated recombinant V3014 strain were generated in vitro. BHK-21 cells then were
cotransfected by electroporation with the pVR21 and helper RNAs, and culture
supernatants were harvested at 30 h after transfection. The generation of VRPs
expressing the F protein of the related virus RSV (used in the present studies as
a heterologous virus control) was previously described (24).
VRP titration. Serial dilutions of VRPs encoding hMPV F (designated VRP-
MPV.F) or hMPV G (designated VRP-MPV.G) were used to infect BHK cells
in eight-chamber slides (Nunc) for 20 h at 37°C. Infected BHK cells were fixed
and immunostained for VEE nonstructural proteins. Infectious units then were
calculated from the number of VEE protein-stained cells per dilution and con-
verted to infectious units (IU) per milliliter.
Formalin-inactivated hMPV (FI-hMPV) preparation. Sucrose gradient-puri-
fied hMPV strain A2 (TN 94-49) was prepared as previously described (49).
Purified hMPV was inactivated by the addition of 37% formaldehyde solution
(one part Formalin per thousand parts hMPV) for 72 h at 37°C. The solution
then was centrifuged at 50,000  g for 1 hour at 4°C. The resulting pellet was
then resuspended 1:25 in serum-free OptiMEM and precipitated with aluminum
hydroxide (4 mg/ml) for 30 min. The precipitate was collected by centrifugation
for 30 min at 1,000  g, resuspended 1:4 in serum-free OptiMEM, and stored at
4°C (44).
Immunofluorescence staining. BHK cells were infected at a multiplicity of
infection (MOI) of 5 with VRP-MPV.F or VRP-MPV.G in eight-chamber slides
(Nunc) for 18 h at 37°C. Infected BHK cells were fixed in 80% methanol for 1
hour at 4°C. The cells then were blocked with phosphate-buffered saline
(PBS)–3% bovine serum albumin (BSA) for 2 hours at room temperature.
Monoclonal antibody against hMPV F or hMPV polyclonal guinea pig serum
(1:1,000 dilution in PBS–1% BSA) was added and allowed to incubate for 1 hour
at room temperature. Cells were washed extensively with Tris-buffered saline–
0.5% Tween 20 (TBST) after incubation with primary antibodies, and secondary
goat anti-mouse or goat anti-guinea pig AlexaFluor C568-conjugated antibodies
were added (1:1,000 dilution in TBST–1% BSA) to the cells for an additional
hour. The slide then was washed with TBST and mounted with Prolong antifade
medium (Invitrogen, Carlsbad, CA). The slide was visualized using an LSM510
inverted laser scanning confocal microscope (Carl Zeiss Microimaging, Thorn-
wood, NY).
Vaccination and challenge of mice or cotton rats. DBA/2 mice were anesthe-
tized with isoflurane and vaccinated intranasally with various titers of VRP-
MPV.F or VRP-MPV.G in a 100-l inoculum. Control groups were inoculated
via the same route with PBS, 105.9 PFU of hMPV subgroup A2 wild-type strain
TN/94-49, or 106 infectious units of VRPs encoding the RSV F gene (VRP-
RSV.F). Mice that were vaccinated with VRPs were boosted with the same dose
2 weeks later. For histopathology and cytokine gene expression studies, a sub-
group of animals was vaccinated once with 50 l of FI-hMPV in each hind leg
intramuscularly. The mice then were observed for clinical signs daily and bled on
day 42 to follow immune responses.
Twenty-eight days after the second immunization (day 42), mice from VRP-
MPV.F- and VRP-MPV.G-vaccinated groups and mice from the control groups
were challenged with 105.9 PFU of the hMPV subgroup A2 strain TN/94-49 or
subgroup B1 strain TN/98-242 intranasally. To monitor virus replication in the
upper and lower respiratory tracts, nasal turbinates and lungs were harvested on
day 4 postchallenge and subsequently assayed for virus titer. Similarly, cotton rats
were vaccinated on day 0 and day 14 with 106 IU of VRP-MPV.F or VRP-
MPV.G intranasally in groups of four. Control groups were inoculated intrana-
sally with PBS, 105.9 PFU of hMPV TN/94-49, or 106 IU of VRP-RSV.F. They
then were bled on day 35 to monitor immune responses, were challenged with
105.9 PFU of hMPV TN/94-49 on day 42, and were sacrificed on day 46. Lung and
nasal turbinates were harvested separately and homogenized to determine viral
titers.
BAL fluid and nasal wash collection. A subset of animals was sacrificed on day
42 (28 days after the second immunization) to collect bronchoalveolar lavage
(BAL) fluid and nasal wash fluid. BAL fluids were collected by ligation of the
trachea with a suture and insertion of a 23-gauge blunt needle into the distal
trachea, followed by three in-and-out flushes of the airways with 3 ml of sterile
PBS. Nasal washes were obtained by flushing 3 ml PBS through the upper
trachea and out the nasal orifice into a sterile receptacle. Both BAL and nasal
washes were concentrated 10-fold using 10-kDa molecular weight cutoff Centri-
con concentrators (Millipore, Bedford, MA).
F protein- and G protein-specific antibody assay. Sera collected at day 42 from
DBA/2 mice were tested for the presence of F or G protein-specific antibodies.
Concentrated nasal washes and BAL fluids also were tested. Briefly, 150 ng/well
of purified hMPV F protein or hMPV G protein was adsorbed onto Immulon 2B
plates overnight in carbonate buffer (pH 9.8) at 4°C. Recombinant F protein was
generated as described previously (13), and recombinant G protein was pro-
duced by similar methods (A. B. Ryder, A. B. Podsiad, S. J. Tollefson, and J. V.
Williams, unpublished data). The plates then were blocked with 3% BSA in PBS
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for 2 h at room temperature. After thorough washing with TBST–1% BSA, serial
dilutions of serum, nasal wash, or BAL fluid samples were added to the plate and
allowed to incubate for 1 hour at room temperature. The plates were washed
again, and horseradish peroxidase (HRP)-conjugated anti-mouse immunoglob-
ulin A (IgA; 1:500 dilution) or IgG (1:5,000 dilution) antibodies were added
(Southern Biotechnology, Birmingham, AL) and allowed to incubate for another
hour. Finally, the plates were washed and 100 l of One-Step Turbo TMB
peroxidase substrate (Pierce, Rockford, IL) was added per well to quantify the
relative amounts of F-specific or G-specific IgA or IgG in the samples. The
reactions then were stopped by adding 50 l of 1 M HCl and the absorbance of
the samples was read at 450 nm. The enzyme-linked immunosorbent assay
(ELISA) titers were expressed as the reciprocal titer of serum in which the
absorbance was twice the background absorbance. Background absorbance was
determined from the average optical density at 450 nm in PBS-incubated control
wells.
Virus-neutralizing antibody assay. Sera collected were used to study the pres-
ence of hMPV-neutralizing antibodies as previously described (49). Serum sam-
ples were tested for neutralizing activity against subgroup A1 strain TN/96-12,
subgroup A2 strain TN/94-49, subgroup B1 strain TN/98-242, and subgroup B2
strain TN/99-419 of hMPV. Briefly, a viral suspension that was standardized to
yield 50 plaques per well in a 24-well plate was used. An aliquot of the hMPV
suspension was incubated with serial dilutions of the serum samples. After an
hour, the suspension was absorbed onto LLC-MK2 cells and then overlaid an
hour later with a semisolid methylcellulose overlay containing 5 g/ml of trypsin.
After 4 days, the cell culture monolayers were fixed and stained by immunoper-
oxidase using hMPV-specific polyclonal guinea pig serum to identify plaques.
Plaques were counted, and plaque reduction was calculated by regression anal-
ysis to provide a 60% plaque reduction titer.
Viral plaque titer assay. Serial dilutions of nasal turbinate or lung homoge-
nates were inoculated onto LLC-MK2 cell monolayer cultures, and plaque assays
were performed as described above. The viral titer was determined by multiply-
ing the number of plaques by the reciprocal sample dilution, divided by tissue
weights, and expressed as PFU per g of tissue.
Lung histopathology studies. Four days after hMPV challenge, mice were
euthanized via CO2 inhalation and lungs were harvested. To preserve the struc-
tural integrity of the lungs, 1 ml of 10% neutral buffered formalin was instilled
into the lungs via tracheotomy, followed by ligation of the trachea with sutures.
The whole lung then was immersed in 10% neutral buffered formalin overnight.
After fixation, the lungs were dehydrated by immersing in 70% ethanol for
another day. The lungs then were embedded in paraffin, sectioned, and stained
with hematoxylin-eosin solution. The severity of airway inflammation was eval-
uated separately for the alveolar tissue, peribronchial tissue, and perivascular
spaces in a group-blind fashion. The degree of inflammation in the alveolar tissue
was graded as follows: 0, normal; 1, increased thickness of the interalveolar septa
by edema and cell infiltration; 2, luminal cell infiltration; 3, abundant cell infil-
tration; 4, inflammatory patches evident. The degree of inflammation in the
peribronchial and perivascular spaces was graded as follows: 0, no infiltrate; 1,
slight cell infiltration; 2, moderate cell infiltration; 3, abundant cell infiltration. In
each tissue section, 10 alveolar tissue fields, 10 airways, and 10 blood vessels were
analyzed using 200 magnification. Mean scores were calculated for each
mouse, and an average score was reported for each animal group.
Cytokine gene expression in the lungs after hMPV challenge. Lungs from
unvaccinated and vaccinated mice were harvested 4 days after hMPV challenge
and placed in RNAlater solution (Ambion, Austin, TX) until further analysis.
Lungs were homogenized using the Omni-tip PCR kit (Omni International,
Marietta, GA), and RNA was extracted using the RNeasy Mini kit (Qiagen,
Valencia, CA) according to the manufacturer’s protocol. Primers and probes for
real-time quantitative PCR were purchased from Applied Biosystems (Foster
City, CA) to measure Th1 or Th2 cytokine transcript levels based on GenBank
sequences for murine glyceraldehyde-3-phosphate dehydrogenase, gamma inter-
feron (IFN-), and interleukin-2 (IL-2), IL-4, IL-5, IL-10, and IL-12. Probes
were labeled at the 5 end with 6-carboxyfluorescein and at the 3 end with the
nonfluorescent quencher Blackhole Quencher 1 (Operon Biotechnologies,
Huntsville, AL). Reverse-transcribed real-time PCR was performed using a
Quantitect probe RT-PCR kit (Qiagen, Valencia, CA) and a SmartCycler II
(Cepheid, Sunnyvale, CA) using 1 g of extracted mRNA. The parameters used
were 1 cycle of 50°C for 2 min, 1 cycle of 95°C for 10 min, and 40 cycles of 95°C
for 15 s and 60°C for 1 min. Reactions were performed in triplicate, with a
no-template sample used as a negative control. Relative amounts of cytokine
gene transcripts expressed were normalized to those of the glyceraldehyde-3-
phosphate dehydrogenase housekeeping gene, and uninfected mice were used as
baseline controls. Differences in mRNA levels were computed using the Ct
method and compared to values for uninfected mice.
Statistics. Prism software was used to plot and analyze the data (Graphpad
Software Inc., San Diego, CA). All data were expressed as geometric means and
their standard deviations. Experimental groups were compared using Mann-
Whitney rank sum tests.
RESULTS
Cloning and expression of hMPV antigens using VRPs.
hMPV fusion (MPV.F) and attachment (MPV.G) genes were
cloned into the VEE replicon vector as previously described
(32). VRPs then were produced in BHK cells by cotransfecting
RNA transcribed in vitro from the replicon vector with tran-
scripts of two separate plasmids encoding VEE capsid and
envelope proteins in trans. To ensure these replicons expressed
the desired antigens, BHK cells were infected at an MOI of 5
with VRPs. Antigen expression then was measured by immu-
nostaining infected cells with guinea pig polyclonal hMPV-
specific antibodies. A robust amount of hMPV F or G protein
was expressed, as evidenced by the intense staining of infected
BHK cells with hMPV-specific antibodies (Fig. 1B and D)
compared to uninfected cells (Fig. 1A and C). Examination of
infected cells by confocal microscopy showed a Golgi appara-
tus and membrane-bound expression pattern for hMPV F pro-
tein, while staining of cells infected with MPV.G VRPs showed
a membrane-bound pattern. Western blot assays also were
used to confirm the presence of hMPV F or G protein expres-
sion in BHK-infected cell lysates (data not shown).
Systemic IgG and mucosal IgA responses in VRP-vaccinated
mice. To assess if VRPs induced systemic humoral immune
responses, we measured the reciprocal endpoint titers of
hMPV F- or G-specific IgG antibodies in the serum of vacci-
A B
C D
FIG. 1. Expression of hMPV proteins from VRP-infected BHK
cells. BHK cells were either mock infected (A and C), infected at an
MOI of 5 with VRP-MPV.F (B), or infected at an MOI of 5 with
VRP-MPV.G (D). Cells then were fixed after 18 h and immunostained
for hMPV F (A and B) or hMPV G (C and D) protein expression using
guinea pig polyclonal anti-hMPV antibodies.
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nated mice by ELISA. Intranasal inoculation of hMPV F-
VRPs induced significantly higher titers of hMPV F-specific
IgG in the sera of vaccinated mice (about eightfold higher in
both the 106 and 105 IU groups) than in unvaccinated animals.
These animals possessed twofold-higher antibody titers com-
pared to mice infected once with hMPV, a difference that did
not reach statistical significance (P  0.22). Similarly, mice that
were vaccinated with VRP-MPV.G showed robust levels of
hMPV G-specific IgG in serum (298-fold and 20-fold higher in
106 and 105 IU groups, respectively) compared to unvaccinated
control animals (Table 1).
Mucosal hMPV F-specific or G-specific IgA antibodies also
were detected in the nasal washes and BAL fluids of VRP-
MPV.F- or VRP-MPV.G-vaccinated mice, respectively, which
represent immunity in the upper or lower respiratory tracts of
vaccinated animals (Fig. 2A and B). Significantly higher titers
of hMPV F-specific or hMPV G-specific antibodies were ob-
served in the BAL fluids of VRP-MPV.F- or VRP-MPV.G-
vaccinated mice compared to hMPV-infected mice (P 
0.008), possibly due to repeated exposure to antigens during
priming and boosting of the VRP-vaccinated animals. Alter-
natively, the higher anti-F and anti-G BAL antibody titers
could be due to presentation of the viral antigens from a
different target cell in the case of VRP vaccination.
Neutralizing activity of antibodies in the sera of VRP-vac-
cinated animals. The presence of circulating neutralizing an-
tibodies is an important parameter that has been implicated in
protecting the lower respiratory tract against respiratory viral
infection, including against hMPV. Therefore, we measured
neutralizing activity in the sera from VRP-vaccinated mice or
cotton rats against subgroup A or B hMPV strains in a 60%
plaque reduction assay. Mice vaccinated with PBS or VRP
expressing RSV F protein, used as a heterologous virus con-
trol, did not generate any detectable neutralizing titer against
either subgroup A or B hMPV strains. Intranasal vaccination
with VRP-MPV.F induced at least a 2.3-log2 (5-fold) or 1.8-
log2 (3.5-fold) increase in serum neutralizing antibody titer
against the A2 or A1 subgroup of hMPV compared to PBS-
vaccinated mice (Table 2). Neutralizing activity against sub-
group A2 strain MPV was higher than against the subgroup A1
strain in these animals. When these sera were tested against
subgroup B hMPV in our 60% plaque reduction assay in vitro,
all sera tested had minimal neutralizing activity toward sub-
group B hMPV. There was some neutralizing activity at the
lowest serum dilution 1:20 which, however, did not reach our
60% plaque reduction criterion in two separate experiments
(Table 2). Surprisingly, infection with subgroup A2 hMPV did
not induce serum antibodies that could neutralize subgroup B
viruses in vitro. Neutralizing titers also were not detected in
mice vaccinated with VRP-MPV.G, despite the presence of
hMPV G-specific IgG in these animals (Table 1). Mice that
were infected with a subgroup A2 strain of hMPV had a neu-
tralizing titer of 7.7 log2 and 6.3 log2 against subgroup A2 and
A1 strains of hMPV, respectively, but very little neutralizing
activity against subgroup B hMPV.
In cotton rats, a similar trend was observed for neutralizing
activity against subgroup A hMPV. Intranasal vaccination with
106 IU of VRP-MPV.F induced reciprocal neutralizing titers
of 6.7 log2 and 5.7 log2 against subgroup A2 and A1 strains of
hMPV, compared to 9.6 log2 and 6.0 log2 from hMPV-infected
FIG. 2. VRP-MPV.F induced hMPV-F- or hMPV-G-specific anti-
bodies in the mucosal secretions of VRP-vaccinated mice. DBA/2 mice
were vaccinated intranasally with 106 infectious units of VRP-MPV.F
or VRP-MPV.G on days 0 and 14. Nasal washes (A) or BAL fluids
(B) were obtained from vaccinated mice 28 days postvaccination. An
MPV-F- or MPV-G-specific enzyme-linked immunosorbent assay was
performed on the samples with HRP-conjugated anti-mouse IgA an-
tibodies. The amount of binding was determined from absorbance
(optical density [OD]) of HRP-substrate complexes at 450 nm.
TABLE 1. Serum antibody responses against hMPV F and G
proteins in immunized DBA/2 mice
Immunization Dose(log10 IU or PFU)
Serum reciprocal endpoint
ELISA titer (mean log2
titer 	 SD) againsta:
hMPV-F hMPV-G
PBS 9.6 	 0.5 4.4 	 0.2
VRP-RSV.F 6 9.8 	 0.5 4.3
VRP-MPV.F 6 12.9 	 1.5** 4.6 	 0.6
5 12.8 	 1.7* ND
4 10.4 	 0.8 ND
VRP-MPV.G 6 9.8 	 0.4 12.3 	 1.1**
5 ND 8.7 	 1.5**
4 ND 7.3 	 2.1
hMPV 5.9 11.8 	 1.0** 5.0 	 1.5
a Statistical significance of the serum reciprocal endpoint ELISA titer com-
pared to the PBS-vaccinated group. *, P 
 0.05; **, P 
 0.01. ND, not deter-
mined.
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animals (Table 2). The neutralization responses were higher in
cotton rats than mice when immunized with hMPV, likely
because the cotton rat is a more permissive model for hMPV
infection, as evidenced by the higher viral titers in the nasal
turbinates of these animals (Table 3).
Viral titers in lungs and nasal turbinates after challenge in
vaccinated animals. To assess the protective efficacy of VRP
vaccines in vivo, we measured hMPV titers in the lungs and
nasal turbinates of mice and cotton rats following intranasal
hMPV subgroup A2 challenge. Mice or cotton rats vaccinated
with VRP-MPV.F had no detectable challenge hMPV titers in
the lungs (at least a 2.2-log10 [158-fold] or 1.9-log10 [79-fold]
reduction in mice or cotton rats, respectively). Reduced
amounts of hMPV also were observed in the nasal turbinates
of VRP-MPV.F-vaccinated animals (1.0-log10- [10-fold] or 2.3-
log10 [200-fold] reduction in mice or cotton rats, respectively).
Previous infection with hMPV subgroup A2 induced immunity
resulting in a reduction of hMPV challenge titers to undetect-
able levels in both the upper and lower respiratory tracts. In
contrast, mice or cotton rats vaccinated with VRP-MPV.G
were not protected from hMPV challenge in either the lungs or
nasal turbinates (Table 3), which is consistent with the lack of
serum neutralizing antibodies we observed. In addition, we
challenged our vaccinated mice with a subgroup B1 strain
hMPV. In the lungs of VRP-MPV.F-vaccinated mice, viral
titers were reduced 1.8 log10 (63-fold) compared with the PBS-
vaccinated group. This surprising reduction was possibly due to
the presence of a low level of neutralizing antibodies in these
animals. In a semipermissive mouse model, a low amount of
neutralizing antibodies may be sufficient to reduce hMPV rep-
lication in the lower respiratory tract. In animals previously
infected with an MPV subgroup A2 strain, we observed a
similar magnitude of viral titer reduction in the lungs when
animals were challenged with a subgroup B1 strain virus.
Histopathology of lungs after challenge in vaccinated ani-
mals. We evaluated the extent of cellular infiltrates in the
perivascular, peribronchial, and alveolar spaces in the lungs of
mice vaccinated with VRPs and then challenged with wild-type
hMPV. In animals that received mock PBS vaccination, a min-
imal amount of infiltration was observed 4 days post-hMPV
infection. In animals that were previously infected with hMPV,
reinfection of mice with hMPV caused a dramatic increase in
cellular infiltrates in the perivascular, peribronchial, and alve-
olar spaces of the lungs. There was also a moderate increase in
mononuclear infiltrates in the alveolar, peribronchial, and
perivascular spaces of animals that received VRP-MPV.F or
VRP-MPV.G when challenged with wild-type hMPV. The his-
topathology scores were comparable and not statistically dif-
ferent between animals that were vaccinated with VRP-
MPV.F and those previously infected with hMPV when both
groups were challenged with wild-type hMPV, although mice
vaccinated with VRP-MPV.F did show a trend of decreased
severity of inflammation in the peribronchial and perivascular
tissues upon challenge. In contrast, animals that were vacci-
TABLE 2. Serum neutralizing antibody responses against various hMPV strains in immunized DBA/2 mice or cotton rats
Immunization Dose(log10 IU or PFU)
60% plaque reduction serum neutralizing titer (mean log2 titer 	 SD) against hMPVa in:
DBA/2 mice Cotton rats
A1 A2 B1 B2 A1 A2 B1 B2
PBS 4.3b 4.3 4.3 4.3 4.3 4.3 4.3 4.3
VRP-RSV.F 6.0 4.3 4.3 4.3 4.3 4.3 4.3 4.3 4.3
VRP-MPV.F 6.0 6.1 	 1.7 6.6 	 1.9 4.3 4.3 5.7 	 1.2 6.7 	 2.3 4.3 4.3
VRP-MPV.G 6.0 4.3 4.3 4.3 4.3 4.3 4.3 4.3 4.3
MPV A2 5.9 6.3 	 1.2 7.7 	 1.3 4.3 4.3 6.0 	 0.6 9.6 	 0.9 4.3 4.3
a The hMPV subgroup A1 strain was TN/96-12, the subgroup A2 strain was TN/94-49, the subgroup B1 strain was TN/98-242, and the subgroup B2 strain was
TN/99-419.
b The lower limit of detection was 4.3 log2 for the hMPV neutralization titer.
TABLE 3. hMPV titers in lungs or nasal turbinates of immunized DBA/2 mice or cotton rats following wild-type subgroup
A2 or B1 hMPV challenge
Immunization
MPV titer following challenge (mean log10 PFU/g tissue 	 SD)






PBS 3.9 	 0.4 3.5 	 0.2 3.5 	 0.3 3.5 	 0.3 3.4 	 0.8 4.5 	 0.4
VRP-RSV.F 3.4 	 0.2 3.4 	 0.1 3.3 	 0.5 3.8 	 0.2 4.2 	 0.0 4.5 	 0.6
VRP-MPV.F 1.7b 2.5 	 0.5d 1.7b 3.0 	 0.3 1.5c 2.2 	 0.5f
VRP-MPV.G 3.0 	 0.7 3.0 	 0.3 3.6 	 0.2 3.4 	 0.4 3.5 	 0.3 4.6 	 0.3
MPV A2 1.7b 2.0b 1.7b 2.2 	 0.3e 1.5c 2.0c
a The designation in parentheses indicates the subgroup of hMPV used for challenge.
b The lower limit of detection was 1.7 log10 or 2.0 log10 for the lungs or nasal turbinates of DBA/2 mice, respectively.
c The lower limit of detection was 1.5 log10 or 2.0 log10 for the lungs or nasal turbinates of cotton rats, respectively.
d Two of five mice had an undetectable hMPV A2 titer in the nasal turbinates.
e Two of five mice had an undetectable hMPV B1 titer in the nasal turbinates.
f Three of four cotton rats had an undetectable hMPV A2 titer in the nasal turbinates.
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nated with a single dose of formalin-inactivated hMPV and
challenged with wild-type virus exhibited extensive cell infiltra-
tions in the perivascular, peribronchial, and alveolar spaces,
which were evidenced by the increased histopathology scores
compared to other vaccination groups (Table 4). This phenom-
enon is consistent with previous findings (51).
Cytokine mRNA expression in lungs of vaccinated mice af-
ter challenge. Aberrant cytokine responses and enhanced dis-
ease after subsequent natural exposure have been observed in
animals or humans vaccinated with certain nonreplicating
paramyxovirus vaccines. Recently, formalin-inactivated hMPV
has been shown to induce a Th2-biased cytokine response and
aggravated disease in experimental animals (51). We measured
cytokine mRNA levels in the lungs of VRP-vaccinated mice
after hMPV challenge to investigate if VRP vaccines would
cause such biased responses. For each of the cytokine mRNAs
tested, hMPV-infected mice had increased lung cytokine
mRNA levels over uninfected controls. The mRNA expression
levels of IFN-, IL-4, IL-10, IL-12p40, and IL-13 were not
statistically different between groups, with two exceptions.
There was a 2.6-fold reduction of IFN- gene expression in the
lungs of VRP-MPV.F-vaccinated mice compared to PBS con-
trols and a 2.1-fold increase in IL-10 gene expression in the
lungs of VRP-MPV.G-vaccinated mice compared to PBS con-
trols. As predicted, in formalin-inactivated hMPV-vaccinated
animals, there was a statistically significant decrease in IFN-
and IL-12p40 mRNA and a statistically significant increase in
IL-13 compared to PBS controls (Table 5).
DISCUSSION
In this study, we have described the molecular construction
of a new experimental vaccine and approach to hMPV vacci-
nation and provided a comprehensive preclinical evaluation of
this new vaccine candidate. The studies provide a thorough
investigation of immunogenicity (binding and neutralizing an-
tibodies and mucosal and systemic responses), wild-type chal-
lenge with homologous or separate clade and separate sub-
group viruses, cross-neutralization studies of all four clades,
histopathology, cytokine profiling of the response, and data in
two animal species. We demonstrated that VEE replicon par-
ticles encoding hMPV F protein were immunogenic in mice
and cotton rats when delivered intranasally. The extent of
responses was comparable to those elicited by wild-type hMPV
infection.
Robust hMPV protein expression by VRPs was confirmed
by immunostaining of infected BHK cells with polyclonal
hMPV antisera. When these VRPs were inoculated into mice
and cotton rat intranasally, they elicited significant levels of
hMPV-specific IgA antibodies in both the upper and lower
respiratory tracts. Local virus-specific IgA secretion on the
mucosal surfaces has been shown to be associated with pro-
tection of individuals from respiratory virus infections (17, 19,
26). Moreover, we detected systemic IgG antibodies against F
or G antibodies in vaccinated animals. hMPV F-specific anti-
bodies also possessed neutralizing activity against hMPV. The
cross-neutralizing activities of sera from VRP-vaccinated ani-
mals against four different strains of the hMPV representing
the four major genotypes were variable. Since our hMPV F
vaccines were constructed based on the nucleotide sequence
obtained from an hMPV subgroup A2 clinical isolate, neutral-
izing activity toward the homologous subgroup A2 strain was
the highest. VRP vaccination induced a significant, but lower,
neutralizing antibody titer toward an hMPV subgroup A1
strain. It was surprising that serum from VRP-vaccinated an-
imals neutralized hMPV subgroup B viruses only somewhat at
the lowest dilution (1:20), given that the homology of the F
gene between the subgroups is 95%. This result is different
from some of the published data, in which serum cross-neu-
tralization and cross-protection were found when animals were
vaccinated with one hMPV subgroup and challenged with an-
other hMPV subgroup (21, 33, 35, 41). We reasoned that the
difference in hMPV F sequences between the subgroups, al-
though small, may contribute to conformational differences in
TABLE 4. Histopathology scores of lung tissues in vaccinated mice




PBS 0.4 	 0.4 0.1 	 0.1 0.2 	 0.1
MPV 0.8 	 0.2 0.9 	 0.2 1.2 	 0.1
VRP-MPV.F 1.0 	 0.3 0.6 	 0.2 0.7 	 0.3
VRP-MPV.G 0.8 	 0.5 0.3 	 0.1 0.4 	 0.2
VRP-RSV.F 0.7 	 0.2 0.5 	 0.4 0.4 	 0.3
FI-MPV 1.4 	 0.2 1.1 	 0.2 1.8 	 0.5
a Lung sections were viewed and scored by a pathologist in a group-blind
fashion. Scores ranged from 0 (normal) to 3 or 4 (severe), as described in
Materials and Methods.
TABLE 5. Cytokine mRNA expression in lungs of immunized DBA/2 mice following wild-type subgroup A2 hMPV challenge
Immunization
Mean fold difference in cytokine gene expression vs uninfected controls (range)a
IFN- IL-4 IL-10 IL-12 p40 IL-13
PBS 8.3 (4.6–17.9) 2.2 (1.3–5.1) 3.7 (2.6–7.0) 9.3 (6.2–14.2) 15.3 (7.4–46.6)
VRP-RSV.F 5.4 (4.1–8.6) 1.8 (1.4–3.2) 3.9 (2.5–5.2) 9.7 (3.7–16.9) 11.6 (4.2–24.0)
VRP-MPV.F 3.2 (2.2–4.9)* 2.2 (1.1–3.7) 4.4 (2.1–6.7) 15.5 (10.9–23.9) 10.8 (6.7–14.5)
VRP-MPV.G 10.8 (6.3–19.5) 1.9 (1.1–2.9) 7.8 (4.7–10.0)* 12.3 (6.3–19.8) 15.8 (6.3–24.5)
MPV 8.3 (4.0–10.5) 2.1 (1.4–3.6) 4.9 (2.3–9.3) 14.8 (9.0–21.9) 6.0 (3.3–13.9)
FI-MPV 3.0 (2.1–6.8)* 4.0 (2.1–8.1) 2.9 (1.5–7.4) 4.7 (2.3–7.5)* 82.7 (27–208)*
a Values in parentheses indicate the range of fold differences between five mice in each group. *, statistically significant group difference compared to PBS-vaccinated
group (P 
 0.05; Mann-Whitney test).
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structure that are important for neutralization. This lack of
cross-neutralization deserves further study.
Also surprising was the finding that the presence of elevated
titers of hMPV G-specific antibodies in vaccinated animals did
not neutralize hMPV. Unlike RSV, the G protein did not seem
to be a neutralizing antigen for hMPV in these studies and did
not contribute to protection against challenge. This finding is
not unique to VRP vaccination. The lack of neutralizing anti-
body induction by hMPV G was demonstrated recently by our
group using purified hMPV G protein as an immunogen in
cotton rats (Ryder et al., unpublished) and by another group
using a recombinant parainfluenza virus vector to deliver
hMPV G protein in hamsters (33). The role of hMPV G
protein in viral pathogenesis is still not defined, although it is
presumed to be an attachment protein, possibly with immuno-
modulation properties based on its homology with the RSV G
protein (8, 30, 39).
When mice or cotton rats vaccinated with VRPs encoding
the hMPV F gene were challenged with wild-type hMPV A2,
the challenge virus replication was reduced to lower than de-
tectable levels in the lungs. The reduction correlated well with
the level of hMPV serum neutralizing antibody in the animals.
This finding is similar to that seen in RSV; a RSV serum
neutralizing titer of 1:380 protected cotton rats from RSV
infection (31). The challenge hMPV titer in the nasal turbi-
nates, however, was not completely reduced in some animals.
VRP-MPV.F-vaccinated animals did have significantly re-
duced titers in the nasal turbinates, possibly due to the pres-
ence of mucosal hMPV-specific IgA antibodies. The incom-
plete protection of the nose could be due to several factors.
One is that the hMPV-specific IgA level induced in the nasal
turbinates appeared to be at a lower level than in the lungs. In
the lungs, both hMPV-specific IgA in the BAL fluids and
serum Ig antibodies contribute to protection, while in the nasal
turbinates, hMPV-specific IgA was solely responsible for pro-
tection. This has been demonstrated with Sendai virus in mice
(25). Second, cellular immune responses may be important in
reducing viral replication in the nasal turbinates. In the RSV
animal model, both RSV-specific CD4 and CD8 cells were
found to be important in conferring protection to animals
against RSV challenge (9, 12, 29). Therefore, cellular immu-
nity also may contribute partly to protection in the upper
respiratory tract. However, in our experience, significant levels
of activated T cells specific for the hMPV F protein are not
detected in DBA/2 animals (data not shown). Several groups
also have found limited cytotoxic T-cell responses against the
hMPV F protein in mice. T-cell epitopes were found to be
restricted exclusively to the M2-1 protein (23) and M2-2 pro-
tein in H-2d major histocompatibility complex class I (MHC-I)
alleles and N protein in H-2b MHC-I alleles (18). It is, how-
ever, likely that a cellular response against hMPV F epitopes
would be found in humans, because of the diverse MHC al-
leles. Another surprising finding is that VRP-MPV.F-vacci-
nated mice did not exhibit a significant neutralizing antibody
titer against subgroup B hMPV, yet they were still protected in
the lungs when challenged with a subgroup B1 hMPV. These
mice may have produced low levels of neutralizing antibodies
that could not be detected. In a semipermissive model, such an
immune response may be sufficient to restrict hMPV B1 rep-
lication in vivo; however, this level of immunogenicity is un-
likely to be protective in humans. Based on amino acid homol-
ogy, we expected that the antigen of one clade in the A
subgroup (A2) would induce cross-reacting antibodies and
protection against an A subgroup virus in the other clade (A1),
and this was found to be the case. It was surprising that our
VEE replicon vaccine encoding a subgroup A virus F protein
was not able to induce complete protection in mice against a
subgroup B hMPV challenge, given the F gene sequence sim-
ilarities between viruses of these subgroups. Possibly, immuni-
zation with F proteins from both subgroups is needed to gen-
erate a broadly effective vaccine for hMPV. In addition, when
mice were immunized with subgroup A2 hMPV and chal-
lenged with subgroup B1 virus, we observed a similar pattern
of protection against B1 hMPV. This intrinsic lack of cross-
neutralization of serum antibodies for subgroup B clinical
isolates in animals infected with subgroup A antigens in ex-
perimental animals deserves further study. The extent of cross-
protection induced by infection with hMPV A or hMPV B is
still under debate. van der Hoogen et al. described the two
major genetic lineages of hMPV as separate serotypes. These
investigators found that when ferrets or nonhuman primates
were infected with hMPV, homologous neutralizing titers
were, in general, greater than heterologous titers, especially at
early time points (41, 42). In addition, a heterologous reinfec-
tion associated with severe disease within 1 month of primary
infection in an otherwise-healthy infant has been documented
(14). On the other side of the argument, others have demon-
strated cross-protection between the two subgroups in animals
that were immunized with recombinant hMPV infection or
inoculation with MPV F protein (3, 34). The extent of homol-
ogous and heterologous cross-protection remains unresolved.
In this study, the data resemble those from the van der Hoogen
group, as we observed homologous neutralizing titers higher
than heterologous titers. This finding could be attributed in
part to the differences between the various clinical hMPV
isolates used among the studies.
One concern for paramyxovirus vaccines is that they could
enhance pulmonary disease by inducing biased Th2-dominant
responses that are exacerbated when the immunized individual
is exposed to natural infection. This is the case for formalin-
inactivated RSV vaccine in infants and more recently FI-
hMPV vaccine in cotton rats (51). Vaccination with VRPs had
been shown to skew toward Th1-type responses (20, 37). We
therefore evaluated lung histopathology and cytokine gene ex-
pression in VRP-vaccinated animals after wild-type hMPV
challenge. Upon hMPV challenge, we found that lungs from
mice that were vaccinated with VRP had similar inflammation
scores as mice that were immunized with hMPV. Lungs from
all hMPV-challenged animals exhibited slight alveolar, peri-
bronchiolar, and perivascular infiltrates and no significant
airway mucus production. As expected, mice vaccinated with
formalin-inactivated hMPV showed significant cellular inflam-
mation in the lungs after hMPV challenge and a corresponding
increase in Th2 cytokine mRNAs. These data establish that the
formalin inactivation effect of altering fusion protein antige-
nicity applies not only to RSV but also to MPV.
Overall, cytokine gene expression was increased in all
hMPV-infected animals compared to uninfected controls.
However, the increase in IFN- gene expression was lower
when comparing animals vaccinated with VRP-MPV.F to
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other groups. This finding may be due to the absence of T-cell
reactivity in DBA/2 mice toward peptides comprising the
hMPV F protein. In the case of RSV, pulmonary disease is
aggravated by aberrant T-cell responses in animal models (9,
43). This finding suggests that the humoral response against
hMPV did not predispose animals to imbalanced immune re-
sponses in vaccinated animals following hMPV exposure.
In summary, we have demonstrated that VEE replicon par-
ticles encoding hMPV F protein induce strong systemic and
mucosal antigen-specific humoral responses and protect ani-
mals against intranasal hMPV challenge. This study provides
strong preliminary evidence that suggests that further devel-
opment of this vaccine candidate for hMPV is warranted.
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